Featured Research

from universities, journals, and other organizations

Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease

Date:
September 4, 2009
Source:
Cell Press
Summary:
A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells. The research findings show that the transplanted cells provided a critical enzyme that was missing in the brains of the experimental mice and represent an important step toward what may be a successful therapeutic approach for a currently untreatable and devastating disease.

A new study finds substantial improvement in a mouse model of a rare, hereditary neurodegenerative disease after transplantation of normal human neural stem cells. The research findings, published by Cell Press in the September 4th issue of the journal Cell Stem Cell, show that the transplanted cells provided a critical enzyme that was missing in the brains of the experimental mice and represent an important step toward what may be a successful therapeutic approach for a currently untreatable and devastating disease.

Infantile neuronal ceroid lipofuscinosis (INCL), commonly known as Batten disease, is a fatal neurodegenerative disease in children. It is caused by a mutation in the gene that makes a crucial enzyme called palmitoyl protein thioesterase-1 (PPT1). A deficiency of PPT1 in the brain causes the abnormal accumulation of a cellular lipid storage material called lipofuscin, which leads to neuron death, a decline in cognitive and motor skills, visual impairment, seizures and premature death. Unfortunately, intravenous enzyme replacement therapy is not a viable treatment approach as it is nearly impossible to get the PPT1 enzyme into the brain.

Although there is currently no effective treatment for INCL, it has been hypothesized that transplanted donor cells might be able to secrete the needed enzyme directly into the host brain. A mouse model of INCL that mimics many aspects of the human disease has been developed and provides an excellent experimental model for testing whether a human neural stem cell transplant may be a beneficial disease treatment. Dr. Nobuko Uchida from StemCells, Inc., in Palo Alto, California led a study that tested this hypothesis with banked human neural stem cells that had been purified, expanded, and preserved.

"We took a novel approach and transplanted normal, nontumorigenic, and nongenetically modified human neural stem cells to deliver the deficient enzyme in the mouse model of INCL," explains Dr. Uchida. "We transplanted self-renewing human neural stem cells because, theoretically, these transplants can provide life-long production of the missing enzyme." Dr. Uchida and colleagues found that the purified human neural stem cells engrafted to the brain of INCL mice, migrated extensively, and produced enough PPT1 in the host mice to elicit significant improvement. Specifically, the INCL mice exhibited reduced lipofuscin, widespread neuroprotection, and a delayed loss of motor coordination.

"Early intervention with neural stem cell transplants into the brains of INCL patients may supply a continuous and long-lasting source of the missing PPT1 and provide some therapeutic benefit through protection of endogenous neurons," concludes Dr. Uchida. "These data support our rationale for continued development in humans and the potential for a medical breakthrough in this deadly disease." Notably, StemCells, Inc., recently reported positive results from the first Phase 1 clinical trials assessing the safety of these human neural stem cells as a potential treatment for Batten disease.

The researchers include Stanley J. Tamaki, StemCells, Inc., Palo Alto, CA; Yakop Jacobs, StemCells, Inc., Palo Alto, CA; Monika Dohse, StemCells, Inc., Palo Alto, CA; Alexandra Capela, StemCells, Inc., Palo Alto, CA; Jonathan D. Cooper, King's College London, London, UK; Michael Reitsma, StemCells, Inc., Palo Alto, CA; Dongping He, StemCells, Inc., Palo Alto, CA; Robert Tushinski, StemCells, Inc., Palo Alto, CA; Pavel V. Belichenko, Stanford University School of Medicine, Stanford, CA; Ahmad Salehi, Stanford University School of Medicine, Stanford, CA; William Mobley, Stanford University School of Medicine, Stanford, CA ; Fred H. Gage, The Salk Institute for Biological Studies, La Jolla, CA; Stephen Huhn, StemCells, Inc., Palo Alto, CA; Ann S. Tsukamoto, StemCells, Inc., Palo Alto, CA; Irving L. Weissman, Stanford University School of Medicine, Stanford, CA; and Nobuko Uchida, StemCells, Inc., Palo Alto, CA.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease." ScienceDaily. ScienceDaily, 4 September 2009. <www.sciencedaily.com/releases/2009/09/090903163556.htm>.
Cell Press. (2009, September 4). Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/09/090903163556.htm
Cell Press. "Transplanted Human Stem Cells Prolong Survival In Mouse Model Of Rare Brain Disease." ScienceDaily. www.sciencedaily.com/releases/2009/09/090903163556.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins